Document Type

Article

Publication Date

7-1-2026

Comments

This article is the author's final published version in World Neurosurgery, Volume 211, July 2026, Article number 125045.

The published version is available at https://doi.org/10.1016/j.wneu.2026.125045.

Copyright © 2026 The Author(s).

Abstract

Objective: Various radiation dosing regimens exist due to tumor size, location, and patient preference. This study evaluated the long-term outcomes of patients with benign meningiomas treated with hypofractionated stereotactic radiotherapy (SRT)at our institution.

Methods: This is a retrospective review of all patients diagnosed with meningioma at our institution who received hypofractionated SRT (5 fractions). Clinical data, including tumor location, size, prior treatments, demographics, radiation dosimetric information, tumor response, and survival were collected. Kaplan-Meier curves were used to assess local control (LC). Acute and late toxicities were evaluated. Patients were included for analysis if they had at least one post-treatment magnetic resonance imaging following therapy.

Results: One hundred-eight patients with benign meningiomas treated between 2013 and 2022 were identified, with 92 included for analysis (n = 16 excluded due to lack of follow-up). With median follow-up of 28 months, the 1-year, 3-year, and 5-year LC rates were 98%, 93%, and 87%, respectively. Fifty-three (58%) patients had partial improvement or resolution of presenting symptoms after completing radiation treatment. When conducting a subgroup analysis excluding patients previously treated with radiation, LC improved to 99%, 97%, and 94% at 1, 3, and 5 years, respectively. Seventeen patients (18%) had G1 or G2 toxicities, with 3 of them experiencing G2 radionecrosis. Tumors were categorized by size and Chi-squared analysis showed no difference in the rate of failure (χ2 = 0.6, P = 0.73).

Conclusions: The SRT regimen of 25 Gy in 5 fractions effectively achieves LC and safety in benign meningiomas. These findings highlight the need for further clinical studies to better understand World Health Organization grade 1 meningiomas.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

Additional Files
Supplemental_Figure_1.jpg (284 kB)
Supplemental_Figure_2.jpg (568 kB)

PubMed ID

42128342

Language

English

Download

Included in

Neurology Commons

Share

COinS